Assessment of the therapeutic efficiency of Bevacizumab in the treatment of diabetic macular edema. Prospective study with 180-day follow-up. 30 eyes of 25 patients with diabetic macular edema underwent a cycle of 3 intravitreal injections (each dose: 1.25 mg/0.05 ml of Bevacizumab – Avastin 100), with an interval of a month between each other. The anterior segment and fundus oculi of the patients were controlled the following day. 30 days after each injection and three months after the last injection, visual acuity (BCVA) and central macular thickness using OCT were determined.
Treatment modality with anti-VEGF (Bevacizumab) in diabetic maculopathy / Malagola, Romualdo; Pattavina, Luigi; Migliorini, Raffaele; Giannotti, Rossella; Arrico, Loredana. - In: OPHTHALMIC RESEARCH. - ISSN 0030-3747. - STAMPA. - 54:Suppl. 1(2015), pp. 20-21. (Intervento presentato al convegno 15th ESASO Retina Academy. October 22-24, 2015, Barcelona, Spain tenutosi a Barcellona, Spagna) [10.1159/000440896].
Treatment modality with anti-VEGF (Bevacizumab) in diabetic maculopathy
MALAGOLA, RomualdoPrimo
;PATTAVINA, LuigiSecondo
;MIGLIORINI, Raffaele;GIANNOTTI, ROSSELLAPenultimo
;ARRICO, Loredana
Ultimo
2015
Abstract
Assessment of the therapeutic efficiency of Bevacizumab in the treatment of diabetic macular edema. Prospective study with 180-day follow-up. 30 eyes of 25 patients with diabetic macular edema underwent a cycle of 3 intravitreal injections (each dose: 1.25 mg/0.05 ml of Bevacizumab – Avastin 100), with an interval of a month between each other. The anterior segment and fundus oculi of the patients were controlled the following day. 30 days after each injection and three months after the last injection, visual acuity (BCVA) and central macular thickness using OCT were determined.| File | Dimensione | Formato | |
|---|---|---|---|
|
Malagola_Treatment modality_2015.pdf
accesso aperto
Note: https://www.karger.com/Article/Abstract/440896
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
